Anti-tumor angiogenesis effect of genetic fusion vaccine encoding murine beta-defensin 2 and tumor endothelial marker-8 in a CT-26 murine colorectal carcinoma model

International Journal of Clinical and Experimental Medicine

Volumn 8, Issue 3, 2015, Pages 4744-4752

  Liu, Ping ^a,b   Xie, Ganfeng ^a   Geng, Peiliang ^a   Zheng, Chenhong ^a   Li, Jianjun ^a   Pan, Feng ^a   Ruan, Zhihua ^a   Liang, Houjie ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b CHANGZHI MEDICAL COLLEGE   (China)

Author keywords

Anti tumor effect; Fusion vaccine; Immunotherapy; MBD2 mTEM8

Indexed keywords

BETA DEFENSIN 2; CANCER VACCINE; GAMMA INTERFERON; PLASMID VECTOR; TUMOR ENDOTHELIAL MARKER 8; TUMOR MARKER; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; CAPILLARY DENSITY; CD8+ T LYMPHOCYTE; CHROMIUM RELEASE ASSAY; COLORECTAL CARCINOMA; CONTROLLED STUDY; DENDRITIC CELL; DNA SEQUENCE; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; IMMUNIZATION; IMMUNOHISTOCHEMISTRY; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; KAPLAN MEIER METHOD; NONHUMAN; PROTEIN EXPRESSION; TUMOR CELL; WESTERN BLOTTING;

MURINAE; MUS;

EID: 84929347031     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. [1] Ferrara N and Kerbel RS. Angiogenesis as a therapeutic target. Nature 2005; 438: 967-974.
2. [2] Grothey A and Galanis E. Targeting angiogenesis: progress with anti-VEGF treatment with large molecules. Nat Rev Clin Oncol 2009; 6: 507-518.
3. [3] Ma WW and Adjei AA. Novel agents on the horizon for cancer therapy. CA Cancer J Clin 2009; 59: 111-137.
4. [4] Marx J. Cancer. Encouraging results for second-generation antiangiogenesis drugs. Sci-ence 2005; 308: 1248-1249.
5. [5] Blagosklonny MV. Antiangiogenic therapy and tumor progression. Cancer Cell 2004; 5: 13-17.
6. [6] Hofmeister V, Vetter C, Schrama D, Brocker EB and Becker JC. Tumor stroma-associated antigens for anti-cancer immunotherapy. Cancer Immunol Immunother 2006; 55: 481-494.
7. [7] St Croix B, Rago C, Velculescu V, Traverso G, Romans KE, Montgomery E, Lal A, Riggins GJ, Lengauer C, Vogelstein B and Kinzler KW. Ge-nes expressed in human tumor endothelium. Science 2000; 289: 1197-1202.
8. [8] Winder T and Lenz HJ. Vascular endothelial growth factor and epidermal growth factor signaling pathways as therapeutic targets for colorectal cancer. Gastroenterology 2010; 138: 2163-2176.
9. [9] Seaman S, Stevens J, Yang MY, Logsdon D, Graff-Cherry C and St Croix B. Genes that distinguish physiological and pathological angiogenesis. Cancer Cell 2007; 11: 539-554.
10. [10] Hotchkiss KA, Basile CM, Spring SC, Bonuccelli G, Lisanti MP and Terman BI. TEM8 expression stimulates endothelial cell adhesion and migration by regulating cell-matrix interactions on collagen. Exp Cell Res 2005; 305: 133-144.
11. [11] Rmali KA, Puntis MC and Jiang WG. TEM-8 and tubule formation in endothelial cells, its potential role of its vW/TM domains. Biochem Biophys Res Commun 2005; 334: 231-238.
12. [12] Davies G, Rmali KA, Watkins G, Mansel RE, Mason MD and Jiang WG. Elevated levels of tumour endothelial marker-8 in human breast cancer and its clinical significance. Int J Oncol 2006; 29: 1311-1317.
13. [13] Cullen M, Seaman S, Chaudhary A, Yang MY, Hilton MB, Logsdon D, Haines DC, Tessarollo L and St Croix B. Host-derived tumor endothelial marker 8 promotes the growth of melanoma. Cancer Res 2009; 69: 6021-6026.
14. [14] Rmali KA, Puntis MC and Jiang WG. Prognostic values of tumor endothelial markers in patients with colorectal cancer. World J Gastro-enterol 2005; 11: 1283-1286.
15. [15] Rmali KA, Watkins G, Harrison G, Parr C, Puntis MC and Jiang WG. Tumour endothelial marker 8 (TEM-8) in human colon cancer and its association with tumour progression. Eur J Surg Oncol 2004; 30: 948-953.
16. [16] Pan J, Jin P, Yan J and Kabelitz D. Anti-ang-iogenic active immunotherapy: a new appro-ach to cancer treatment. Cancer Immunol Im-munother 2008; 57: 1105-1114.
17. [17] Wei YQ, Wang QR, Zhao X, Yang L, Tian L, Lu Y, Kang B, Lu CJ, Huang MJ, Lou YY, Xiao F, He QM, Shu JM, Xie XJ, Mao YQ, Lei S, Luo F, Zhou LQ, Liu CE, Zhou H, Jiang Y, Peng F, Yuan LP, Li Q, Wu Y and Liu JY. Immunotherapy of tumors with xenogeneic endothelial cells as a vaccine. Nat Med 2000; 6: 1160-1166.
18. [18] Wei YQ, Huang MJ, Yang L, Zhao X, Tian L, Lu Y, Shu JM, Lu CJ, Niu T, Kang B, Mao YQ, Liu F, Wen YJ, Lei S, Luo F, Zhou LQ, Peng F, Jiang Y, Liu JY, Zhou H, Wang QR, He QM, Xiao F, Lou YY, Xie XJ, Li Q, Wu Y, Ding ZY, Hu B, Hu M and Zhang W. Immunogene therapy of tumors with vaccine based on Xenopus homologous vascular endothelial growth factor as a model antigen. Proc Natl Acad Sci U S A 2001; 98: 11545-11550.
19. [19] O’Mahony D and Bishop MR. Monoclonal antibody therapy. Front Biosci 2006; 11: 1620-1635.
20. [20] Gattinoni L, Powell DJ Jr, Rosenberg SA and Restifo NP. Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol 2006; 6: 383-393.
21. [21] Bequet-Romero M, Ayala M, Acevedo BE, Ro-driguez EG, Ocejo OL, Torrens I and Gavilondo JV. Prophylactic naked DNA vaccination with the human vascular endothelial growth factor induces an anti-tumor response in C57Bl/6 mice. Angiogenesis 2007; 10: 23-34.
22. [22] Lee SH, Mizutani N, Mizutani M, Luo Y, Zhou H, Kaplan C, Kim SW, Xiang R and Reisfeld RA. Endoglin (CD105) is a target for an oral DNA vaccine against breast cancer. Cancer Im-munol Immunother 2006; 55: 1565-1574.
23. [23] Liu JY, Wei YQ, Yang L, Zhao X, Tian L, Hou JM, Niu T, Liu F, Jiang Y, Hu B, Wu Y, Su JM, Lou YY, He QM, Wen YJ, Yang JL, Kan B, Mao YQ, Luo F and Peng F. Immunotherapy of tumors with vaccine based on quail homologous vascular endothelial growth factor receptor-2. Blood 2003; 102: 1815-1823.
24. [24] Niethammer AG, Xiang R, Becker JC, Wodrich H, Pertl U, Karsten G, Eliceiri BP and Reisfeld RA. A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth. Nat Med 2002; 8: 1369-1375.
25. [25] Felicetti P, Mennecozzi M, Barucca A, Mont-gomery S, Orlandi F, Manova K, Houghton AN, Gregor PD, Concetti A and Venanzi FM. Tumor endothelial marker 8 enhances tumor immunity in conjunction with immunization against differentiation Ag. Cytotherapy 2007; 9: 23-34.
26. [26] Yang D, Biragyn A, Hoover DM, Lubkowski J and Oppenheim JJ. Multiple roles of antimicrobial defensins, cathelicidins, and eosinophil-derived neurotoxin in host defense. Annu Rev Immunol 2004; 22: 181-215.
27. [27] Bowdish DM, Davidson DJ and Hancock RE. Immunomodulatory properties of defensins and cathelicidins. Curr Top Microbiol Immunol 2006; 306: 27-66.
28. [28] Yang D, Chertov O, Bykovskaia SN, Chen Q, Buffo MJ, Shogan J, Anderson M, Schroder JM, Wang JM, Howard OM and Oppenheim JJ. Beta-defensins: linking innate and adaptive immunity through dendritic and T cell CCR6. Science 1999; 286: 525-528.
29. [29] Navid F, Boniotto M, Walker C, Ahrens K, Pro-ksch E, Sparwasser T, Muller W, Schwarz T and Schwarz A. Induction of regulatory T cells by a murine beta-defensin. J Immunol 2012; 188: 735-743.
30. [30] Mei HF, Jin XB, Zhu JY, Zeng AH, Wu Q, Lu XM, Li XB and Shen J. beta-defensin 2 as an adjuvant promotes anti-melanoma immune responses and inhibits the growth of implanted murine melanoma in vivo. PLoS One 2012; 7: e31328.
31. [31] Ahrens K, Schunck M, Podda GF, Meingassner J, Stuetz A, Schroder JM, Harder J and Proksch E. Mechanical and metabolic injury to the skin barrier leads to increased expression of murine beta-defensin-1, -3, and -14. J Invest Dermatol 2011; 131: 443-452.
32. [32] Biragyn A, Surenhu M, Yang D, Ruffini PA, Hai-nes BA, Klyushnenkova E, Oppenheim JJ and Kwak LW. Mediators of innate immunity that target immature, but not mature, dendritic cells induce antitumor immunity when genetically fused with nonimmunogenic tumor antigens. J Immunol 2001; 167: 6644-6653.
33. [33] Ma XT, Xu B, An LL, Dong CY, Lin YM, Shi Y and Wu KF. Vaccine with beta-defensin 2-transduced leukemic cells activates innate and adaptive immunity to elicit potent antileukemia responses. Cancer Res 2006; 66: 1169-1176.
34. [34] Bonuccelli G, Sotgia F, Frank PG, Williams TM, de Almeida CJ, Tanowitz HB, Scherer PE, Hotchkiss KA, Terman BI, Rollman B, Alileche A, Brojatsch J and Lisanti MP. ATR/TEM8 is highly expressed in epithelial cells lining Bacillus anthracis’ three sites of entry: implications for the pathogenesis of anthrax infection. Am J Physiol-cell Ph 2005; 288: C1402-1410.
35. [35] Biragyn A, Tani K, Grimm MC, Weeks S and Kwak LW. Genetic fusion of chemokines to a self tumor antigen induces protective, T-cell dependent antitumor immunity. Nat Biotechnol 1999; 17: 253-258.
36. [36] Ruan Z, Yang Z, Wang Y, Wang H, Chen Y, Shang X, Yang C, Guo S, Han J, Liang H and Wu Y. DNA vaccine against tumor endothelial marker 8 inhibits tumor angiogenesis and growth. J Immunother 2009; 32: 486-491.
37. [37] Wang YS, Wang GQ, Wen YJ, Wang L, Chen XC, Chen P, Kan B, Li J, Huang C, Lu Y, Zhou Q, Xu N, Li D, Fan LY, Yi T, Wu HB and Wei YQ. Immunity against tumor angiogenesis induced by a fusion vaccine with murine beta-defensin 2 and mFlk-1. Clin Cancer Res 2007; 13: 6779-6787.